Publication

ACR •
29 October, 2025 •
•

PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome

David B. Beck, Mael Heiblig, Sinisa Savic, Marcela A. Ferrada, Arsene Mekinian, Onima Chowdhury, Danielle Hammond, Lachelle D. Weeks, Carmelo Gurnari, Yohei Kirino , Sophie Georgin-Lavialle, Sarah A. Buckley, Bryan G. Harder, Sandra Goble, Matthew J. Koster

Available materials

Oral Presentation

Publication

ACR •
28 October, 2025 •
•

Economic Burden of Macrophage Activation Syndrome (MAS) in Patients with Still’s Disease (Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-onset Still’s Disease (AOSD): Analysis of a US National Administrative Claims Database

Michael Marrone, Christopher McPherson, Abiola Oladapo

Available materials

Poster

Publication

ACR •
28 October, 2025 •
•

Nanoencapsulated Sirolimus Plus Pegadricase Reduced Disease Burden in Patients With Uncontrolled Gout: Results From the Phase 3 DISSOLVE Trials

Puja Khanna, Amar Majjhoo, Rehan Azeem, Ben Peace, Bhavisha Desai, Vibeke Strand

Available materials

Oral Presentation

Publication

Characterization of Infusion Reactions Within 1 Hour of Treatment With Nanoencapsulated Sirolimus Plus Pegadricase: Pooled Results From the Phase 3 DISSOLVE I and DISSOLVE II Trials

PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome

Economic Burden of Macrophage Activation Syndrome (MAS) in Patients with Still’s Disease (Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-onset Still’s Disease (AOSD): Analysis of a US National Administrative Claims Database

Nanoencapsulated Sirolimus Plus Pegadricase Reduced Disease Burden in Patients With Uncontrolled Gout: Results From the Phase 3 DISSOLVE Trials

Management of Uncontrolled Gout Among Nephrology Professionals: Findings from a Medical Chart Audit

Effect of Nanoencapsulated Sirolimus plus Pegadricase (NASP) on Kidney Outcomes: Results from the Phase 3 DISSOLVE Studies

Nanoencapsulated Sirolimus Plus Pegadricase (NASP) Reduces Gout Clinical Manifestations in Patients With Uncontrolled Gout (UG) and Stage 3 CKD

Variations in Chronic Refractory Gout Management between Rheumatologists and Nephrologists